Ward D M
Department of Medicine, University of California, San Diego 92103-1990, USA.
Adv Ren Replace Ther. 1997 Apr;4(2):160-73. doi: 10.1016/s1073-4449(97)70043-8.
No wholly satisfactory drug or system has yet been devised for preventing thrombosis in extracorporeal blood circuits needed for renal replacement treatments. Heparin is still regarded by some as a standard approach, but advances in many areas of intensive care unit (ICU) medicine have created the potential for saving the lives of many patients in whom heparin anticoagulation is no longer appropriate. Several nonheparin methods are now readily performed, and the great risk of bleeding that is imposed by the use of heparin demands that citrate or other nonheparin methods be made available in the ICUs of all major medical centers that deal with trauma or major surgical procedures. Details of the practicalities, difficulties, and advantages are compared for low-dose heparin, regional heparin, low-molecular-weight heparin, no-anticoagulant systems, citrate, and other anticoagulants for both intermittent and continuous modalities. The clinical features and complications in individual patients that impact on the selection of the best method of management are reviewed.
对于肾脏替代治疗所需的体外血液回路,尚未设计出完全令人满意的药物或系统来预防血栓形成。肝素仍被一些人视为标准方法,但重症监护病房(ICU)医学许多领域的进展为挽救许多不再适合肝素抗凝的患者生命创造了可能性。现在几种非肝素方法已很容易实施,并且使用肝素带来的大出血风险要求在所有处理创伤或重大外科手术的主要医疗中心的ICU中提供枸橼酸盐或其他非肝素方法。比较了低剂量肝素、局部肝素、低分子量肝素、无抗凝剂系统、枸橼酸盐和其他抗凝剂在间歇性和连续性模式下的实用性、困难和优点。还回顾了影响最佳管理方法选择的个体患者的临床特征和并发症。